Моисеева О. М., Беркович О. А., Виллевальде С. В., Емельянов И. В. Влияние терапии эналаприлом на развитие тромботических и воспалительных изменений при гипертонической болезни. Кардиоваскулярная терапия и профилактика. 2005;4(6, ч.II):32-37.
1. Шальнова С.А., Деев А.Д., Оганов Р.Г. и др. Роль систолического и диастолического давления для прогноза смертности от сердечно–сосудистых заболеваний. Кардиоваск тер профил 2002; 1: 10-5
2. Flack JM, Neaton J, Grimm R, et al. Blood Pressure and Mortality Among Men With Prior Myocardial Infarction. Circulation 1995; 92: 2437-45.
3. JNC-VII: The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; 289: 2560-71.
4. Lip GY, Blann AD. Does hypertension confer a prothrombotic state? Virchow’s triad revisited. Circulation 2000; 101: 218-20.
5. Lip GY, Blann A. Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997; 34: 255-65.
6. Becker BF, Heindl B, Kupatt C, Zahler S. Endothelial function and hemostasis. Z Kardiol 2000; 89: 160-7.
7. Lip GYH. Target organ damage and the prothrombotic state in hypertension. Hypertension 2000; 36: 975-7.
8. DeSouza CA, Dengel DR, Macko RF, et al. Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 1997; 10: 1335-41.
9. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intimamedia thickness and the risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 1997; 96: 1432-7.
10. Simons PC, Algra A, Bots ML, et al. Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease). Circulation 1999; 100: 951-7.
11. Sander D, Kukla C, Klingelhofer J, et al. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: A 3-year follow-up study. Circulation 2000; 102: 1536-41.
12. HOPE Study Investigators. Effects of an angiotensin-converting– enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
13. Lonn EM, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis.The study to evaluate carotid ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-25.
14. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis.The simvastatin/enalapril coronary atherosclerosis trial (SCAT). Circulation 2000; 102: 1748-54.
15. MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. JACC 2000; 36: 438-43.
16. Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Рекомендации экспертов Всероссийского общества кардиологов (ВНОК). Артериальная гипертензия 2001; 7(приложение 1): 1-16.
17. Рогоза А.Н., Никольский В.П., Ощепкова Е.В. и др. Суточное мониторирование артериального давления (Методические вопросы). Под ред. Г.Г. Арабидзе, О.Ю.Атькова. Москва 1997; 44с.
18. Кобалава Ж.Д., Котовская Ю.В. Мониторирование артериального давления: методические аспекты и клиническое значение. Под ред. В.С.Моисеева. Москва 1999; 234c.
19. Devereux RB, Reinchek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-8.
20. Hammond IW, Devereux RB, Alderman MH, et al. Prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. JACC 1986; 7: 639-50.
21. Ашкинази И.Я. Эритроцит и внутреннее тромбопластинобразование. Ленинград «Наука» 1977; 155c.
22. Моисеева О.М., Моисеев С.И., Гуревич В.С. Способ определения деформабельности эритроцитов. Лаб дело 1990; 10: 55-7.
23. Wu KK, Hoak JC. A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 1974; 2: 924-6.
24. Ley K, Lundgren E, Berger E, Arfors K-E. Shear-dependent inhibition of granulocyte adhesion to cultured endothelium by dextran sulfate. Blood 1989; 73: 1324-30.
25. Suda K, Rothen-Rutishauser B, Gunthert M, Wunderli-Allenspach H. Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: endothelial versus epithelial features. In vitro cell dev boil anim 2001; 37: 505-14.
26. Momboli J-V, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 1999; 31: 61-74.
27. Kikuchi Y, Da QW, Fujino T. Variation in red blood cell deformabilitty and posible consequences for oxygen transpot to tissue. Microvasc Res 1994; 47: 222-31.
28. Cicco G, Pirrelli A. Red blood cell (RBC) deformability, RBC aggregability and tissue oxygenation in hypertension. Clin Hemorheol Microcirc 1999; 21: 169-77.
29. Faller DV. Endothelial responses to hypoxic stress. Clin Exp Pharmacol Physiol 1999; 26: 74-84.
30. Ajmani RS. Hypertension and hemorheology. Clin Hemorheol Microcirc 1997; 17: 397-420.
31. Blann AD, Naqvi T, Waite M, McCollum CN von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 1993; 7: 107-11.
32. Blann AD, Nadar S, Lip GY. Pharmacological modulation of platelet function in hypertension. Hypertension 2003; 42: 1-7.
33. Rosenson RS, Hafner JM. Rheological changes in hypertensive patients treated with ramipril. Clin Hemorheol Microcirc 1997; 17: 41-6.
34. Islim IF, Bareford D, Beevers DS. A single (investigator)-blind randomized control trial comparing the effects of quinapril and nifedipine on platelet function in patients with mild to moderate hypertension. Platelets 2001; 12: 274-8.
35. Li-Saw-Hee FL, Beevers DG, Lip GY. Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial. Int J Cardiol 2001; 78: 241-6.
36. Urata H, Kinoshita A, Misono FM, et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-57.
37. Фрейдлин И.С., Тотолян А.А. Клетки иммунной системы. Санкт-Петербург «Наука» 2001; III-V: 390с.
38. Mombouli JV, Vanhoutte PM. Kinins and endothelial control of vascular smooth muscle. Ann Rev Pharmacol Toxicol 1995; 35: 679-705.
39. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95: 1115-8.
40. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS). Circulation 1995; 91: 698-706.
41. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies JAMA 1996; 275: 1507-13.
